Skip to main content
. 2017 Aug 2;2017(8):CD001324. doi: 10.1002/14651858.CD001324.pub5
Methods Randomised trial. Method of randomisation not reported
Participants 309 women attending family planning clinics in Beijing, China
Included only women attending within 72 h of an unprotected intercourse
Excluded women with irregular menstrual periods, who used oral contraceptives and those who had not resumed normal menses after an abortion or delivery
Interventions Mife 25 mg vs Mife 10 mg vs Mife 5 mg
Outcomes Observed number of pregnancies, side effects and changes in menstrual pattern
Notes
  1. Post‐randomisation exclusions not reported

  2. Loss to follow‐up 5.8% (18/309) altogether

  3. Observed pregnancy/expected pregnancy/total number of women: Mife 25 mg 1/6/99; Mife 10 mg 1/7/92; Mife 5 mg 2/7/100

Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Mentioned randomisation but description not adequate
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not mentioned
Blinding (performance bias and detection bias) All outcomes Unclear risk Not mentioned
Incomplete outcome data (attrition bias) All outcomes Low risk Loss to follow‐up reported
Selective reporting (reporting bias) Low risk Reported planned outcomes
Other bias Low risk None detected